SCI & TECH● LOWSep 3 · Sep 3, 2026, 5:55 AM
Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug
Seeking Alpha Tech · global
Ultragenyx shares dropped following the failure of a Phase 3 trial for its Angelman syndrome drug. This outcome is a significant setback for the company's pharmaceutical development efforts.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH32m agoGears of War : E - Day Has Fixed One of the Biggest Problems With Modern Shooterscomicbook.com · United StatesSCI & TECH1h agoBattlefords siblings find fossils that appear 450 million years oldpanow.com · CanadaSCI & TECH1h agoFireSwarm Solutions Recognized Globally Among Cleantech Group 2026 Cleantech 50 to Watch for Wildfire Technology Innovationintelligencer.ca · CanadaSCI & TECH1h agoJapan launches spacecraft to explore Martian moons and bring home soilwdbo.com · United States